The Pentagon’s medical policies for troops have become a flashpoint in broader political fights over military readiness and gender-related care. That debate sharpened on July 15, when Defense Secretary Pete Hegseth announced a new testosterone screening program for service members and Sen. Tammy Duckworth of Illinois publicly challenged the move. Her response placed a national military policy at the center of a new dispute over how the Defense Department defines necessary hormone treatment.
Pentagon announces annual screening program for troops over 30
Defense Secretary Pete Hegseth said on July 15 that the Pentagon will begin annual screening for testosterone deficiency for service members age 30 and older, while making the test voluntary for those under 30, according to the Associated Press and CBS News. Hegseth said the policy is intended to ensure troops have the right hormone levels to perform at their “absolute best,” framing it as part of military health and readiness.
The Pentagon had not, as of the initial reports, released detailed written guidance explaining how the screening will be implemented across the services, what laboratory thresholds will be used, or how treatment decisions will be made. That left unanswered questions about whether the program will apply equally across active-duty men and women and whether follow-up care would include testosterone replacement therapy.
Duckworth, an Iraq War veteran and Democratic senator from Illinois, responded that the program sounded “like gender-affirming care to me,” according to the Associated Press. She and other lawmakers also pressed for any hormone testing framework to be available to both male and female service members, adding another layer to the policy debate as the administration continues to defend its restrictions on transgender military service.
Because Duckworth represents Illinois and serves as one of the Senate’s most prominent veterans on military issues, her criticism gave the dispute a clear state-level political dimension. What is confirmed is that Duckworth publicly tied the Pentagon’s new testosterone initiative to the broader question of hormone-based treatment in the military, highlighting what she described as an inconsistency in policy.
What is not yet known is whether Illinois-based National Guard personnel or reserve members will be affected in the same way as active-duty troops under the Pentagon rollout. The Defense Department has not released a state-by-state implementation plan, and it has not published a full operational timeline showing when specific military installations will begin annual screening.
Duckworth’s comments also carry weight because they intersect with her long-running work on defense oversight in the Senate. Her statement did not change the policy, but it did move the issue from a Pentagon announcement into a broader public argument over who receives hormone-related care in uniform and under what standards. For Illinois readers, the immediate local angle is political rather than logistical: a home-state senator is now one of the highest-profile critics of the program.
Hegseth has presented the screening initiative as a readiness measure, saying troops should receive top-tier medical care so they remain strong, resilient, and deployable, according to CBS News and the Associated Press. That rationale fits a longstanding Pentagon practice of tying routine health programs to force performance, but this case is drawing extra scrutiny because testosterone is itself a hormone treatment issue.
The controversy is sharpened by the Defense Department’s existing policy on gender dysphoria and transgender-related care. Pentagon guidance issued earlier in 2025 said department funding would no longer be used for newly initiated cross-sex hormone therapy related to gender dysphoria, according to Defense Department statements. Congressional research materials and military health policy documents have also described hormone therapy as part of gender-affirming care in certain circumstances.
For service members and military families, the practical next step is waiting for detailed guidance the Pentagon has not yet released. That includes when screenings begin, who qualifies for treatment after testing, whether women will be included on equal terms, and how the department will define deficiency. Until that guidance is published, the clearest confirmed fact is that the policy was officially announced on July 15 and immediately triggered a high-profile challenge from a sitting U.S. senator.